Today, at the Canadian Radiotheranostics Leaders’ Summit (Toronto, ON) the Centre for Probe Development and Commercialization (CPDC) announced that it will be launching a Contract Research Organization (CRO) later this summer, with the aim to address the need to accelerate drug development in the radiopharmaceutical space.

CPDC has a history of advancing nuclear medicine and molecular imaging within the pharmaceutical and medical industry. Founded in 2008, CPDC has become a cornerstone of Canada’s radiopharmaceutical ecosystem. As a not-for-profit organization, CPDC specializes in the discovery, development, and commercialization of molecular imaging probes and targeted radiotherapeutics.

With today’s announcement, CPDC takes one further step toward advancing nuclear medicine, medical isotopes, and nor, development of radiopharmaceuticals.

Martin Poirier (VP of Contract Research at CPDC) revealed that the CRO would offer advisory and consulting services, medical writing, as well as early stage and preclinical laboratory services to support the development of radiopharmaceuticals and radiodiagnostics. Laboratory services will include radiochemistry and radiolabeling, in vitro and in vivo efficacy, safety, toxicity studies, dosimetry and imaging, and more. The CRO will operate internationally.

With this new initiative, CPDC seeks to alleviate the dire need for more service providers to accelerate the development of radiopharmaceuticals, which will ultimately benefit all patients, in Canada and beyond.

More details will be revealed later this summer when the CRO is officially launched.